ALK-Abello A/S (ALK B) DKK0.5 B

Sell:205.40 DKKBuy:205.80 DKKPrice increased1.40 DKK (0.68%)

Prices delayed by at least 15 minutes
Sell:205.40 DKK
Buy:205.80 DKK
Change:Price increased1.40 DKK (0.68%)
Prices delayed by at least 15 minutes
Sell:205.40 DKK
Buy:205.80 DKK
Change:Price increased1.40 DKK (0.68%)
Prices delayed by at least 15 minutes

Company Information

About this company

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Key people

Anders Hedegaard
Executive Vice President - Business Operations and International Marketing
Jacob Glenting
Senior Vice President - Corporate, Portfolio & Product Strategy
Jan Engel Jensen
Senior Vice President - Global Quality
Katja Barnkob
Director, Employee Representative
Nanna Rassov Carlson
Director, Employee Representative
Lars Holmqvist
Director
Peter Halling
President, Chief Executive Officer
Lene Skole-Soerensen
Vice Chairman of the Board
Claus Steensen Solje
Executive Vice President, Chief Financial Officer
Lika Thiesen
Executive Vice President - Global People and Organization
Flora Beiche-Scholz
Executive Vice President - Commercial Operations, Europe
Christian G. Houghton
Executive Vice President - Product Supply
Edward Jordan
Executive Vice President - Commercial Operations, North America
Henriette Mersebach
Executive Vice President - Research and Development
Click to see more

Key facts

  • Shares in issue
    202.57m
  • EPIC
    ALK B
  • ISIN
    DK0061802139
  • Location
    Denmark
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    DKK 41.45bn
  • Employees
    2,721
  • Exchange
    Copenhagen Stock Exchange
  • Index
    Denmark-OMX-Copenhagen-All-Share-Index, TR Equity Denmark Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.